Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

Pediatric Dose Selection and Utility of PBPK in Determining Dose

(2018) Ian E. Templeton et al.   AAPS Journal

Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies

(2018) Paul Malik et al.   Expert Opinion on Drug Metabolism & Toxicology

Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling

(2018) Deni Hardiansyah et al.   mAbs

Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical Pharmacology

(2018) Manuela Grimstein et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys

(2018) Tommy Li et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans

(2018) Tommy Li et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim

(2017) Christoph Niederalt et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products

(2016) Iftekhar Mahmood   AMERICAN JOURNAL OF THERAPEUTICS

Men and mice: Relating their ages

(2016) Sulagna Dutta et al.   LIFE SCIENCES

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

(2014) W. Wick et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Relationships of Monoclonal Antibodies in Children

(2014) Helena Edlund et al.   CLINICAL PHARMACOKINETICS

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

ArrayExpress update—simplifying data submissions

(2014) Nikolay Kolesnikov et al.   NUCLEIC ACIDS RESEARCH

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban

(2013) Stefan Willmann et al.   CLINICAL PHARMACOKINETICS

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

(2013) Timo Rath et al.   CRITICAL REVIEWS IN BIOTECHNOLOGY

Distribution of rat neonatal Fc receptor in the principal organs of neonatal and pubertal rats

(2013) Zehua Tian et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients

(2012) Jochen Tuettenberg et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

(2010) Takuo Suzuki et al.   JOURNAL OF IMMUNOLOGY

Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFκB-TIMP-2 pathway

(2009) Pawel Wisniewski et al.   CELLULAR SIGNALLING

Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice

(2009) Héctor Pérez Montoyo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma

(2008) Susanne Kleber et al.   CANCER CELL

The Ashwell receptor mitigates the lethal coagulopathy of sepsis

(2008) Prabhjit K Grewal et al.   NATURE MEDICINE